

Financial news for XNCR dated on 2020-05-13: Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb In Solid Tumors: 'generally well-tolerated and a confirmed complete response observed at highest dose level tested'

Financial news for XNCR dated on 2020-05-07: Xencor Q1 EPS \$(0.140) Beats \$(0.380) Estimate, Sales \$32.385M Beat \$15.060M Estimate

Financial news for XNCR dated on 2020-03-25: Xencor And Vir Biotechnology Enter License Agreement For Use Of Xtend XmAb Antibody Technology In Investigational Antibodies To Potentially Treat Coronavirus

Financial news for XNCR dated on 2020-03-04: Barclays Initiates Coverage On Xencor with Underweight Rating, Announces \$28 Price Target

Financial news for XNCR dated on 2020-02-25: Guggenheim Securities Upgrades Xencor to Buy, Announces \$43 Price Target

Financial news for XNCR dated on 2020-02-24: Xencor Q4 EPS \$(0.47) Misses \$(0.41) Estimate, Sales \$3.16M Miss \$14.27M Estimate

Financial news for XNCR dated on 2020-02-05: Aimmune Therapeutics Reports License Of Exclusive Global Rights To Xencor's XmAb 7195 For Development Of Next-Gen Food Allergy Treatments; Aimmune to Make Upfront Payment To Xencor Of \$5M In Cash, \$5M In Equity

Financial news for XNCR dated on 2020-01-30: RBC Capital Initiates Coverage On Xencor with Outperform Rating, Announces \$44 Price Target

Financial news for XNCR dated on 2020-01-08: Xencor And Gilead Enter License Agreement For Use Of XmAb Antibody Technologies In Investigational Agents For HIV

Financial news for XNCR dated on 2019-12-27: Xencor shares are trading lower after John Stafford a company director sold 212,939 shares at an average price of \$39.52 per share. NOTE: When an insider sells shares, the market may perceive it as a sign of weak confidence in the company's outlook.

Financial news for XNCR dated on 2019-11-05: Xencor Q3 EPS \$(0.18) Beats \$(0.55) Estimate, Sales \$21.76M Beat \$7.39M Estimate

Financial news for XNCR dated on 2019-08-08: Canaccord Genuity Maintains Buy on Xencor, Raises Price Target to \$52

Financial news for XNCR dated on 2019-08-07: Xencor shares are trading lower after the company reported Q2 earnings results. Multiple firms downgraded the stock following earnings.

Financial news for XNCR dated on 2019-08-07: Guggenheim Downgrades Xencor to Neutral

Financial news for XNCR dated on 2019-08-07: Raymond James Downgrades Xencor to Market Perform

Financial news for XNCR dated on 2019-08-06: Xencor Q2 EPS \$(0.28) Beats \$(0.46) Estimate, Sales \$19.485M Beat \$7.64M Estimate

Financial news for XNCR dated on 2019-06-25: Xencor shares are trading higher after it was announced the company would replace HFF Inc in the S&P SmallCap 600.

Financial news for XNCR dated on 2019-06-24: Xencor To Join S&P SmallCap 600

Financial news for XNCR dated on 2019-06-13: Mizuho Initiates Coverage On Xencor with Buy Rating, Announces \$52 Price Target

Financial news for XNCR dated on 2019-06-03: Xencor Doses First Patient In Phase 1 Study Of XmAb22841 For The Treatment Of Patients With Advanced Solid Tumors

Financial news for XNCR dated on 2019-05-09: Xencor Q1 EPS \$1.38 Up From \$(0.62) YoY, Sales \$111.939M

Financial news for XNCR dated on 2019-04-30: Xencor Announces Partial Clinical Hold Lifted On Phase 1 Study Of XmAb14045

Financial news for XNCR dated on 2019-04-12: Guggenheim Initiates Coverage On Xencor with Buy Rating, Announces \$42 Price Target

Financial news for XNCR dated on 2019-04-02: Xencor And Astellas Enter Collaboration For Novel Bispecific Antibody Program; Astellas To Receive Exclusive Worldwide License To Potential Drug Candidates

Financial news for XNCR dated on 2019-03-27: Berenberg Initiates Coverage On Xencor

with Buy Rating, Announces \$45 Price Target

Financial news for XNCR dated on 2019-03-20: Xencor Inc shares are trading higher after Ronin Capital bought 39,400 shares of the company's stock at an average price of \$29.04 per share.

Financial news for XNCR dated on 2019-03-15: Raymond James Initiates Coverage On Xencor with Outperform Rating, Announces \$40 Price Target

Financial news for XNCR dated on 2019-02-25: Xencor Q4 EPS \$(0.32) Beats \$(0.49) Estimate, Sales \$11.564M Beat \$5.86M Estimate

Financial news for XNCR dated on 2019-02-22: Nomura Downgrades Xencor to Reduce

Financial news for XNCR dated on 2019-02-20: Xencor shares are trading lower after the company announced a partial clinical hold on its Phase 1 study of XmAb14045 following safety reports which potentially linked two patient deaths to the drug.

Financial news for XNCR dated on 2019-02-20: Xencor Announces Partial Clinical Hold On Phase 1 Study Of XmAb14045 Following Safety Reports Submitted On Two Patient Deaths Possibly Related To The Drug

Financial news for XNCR dated on 2019-02-05: Xencor Will Develop, Commercialize Novel IL-15 Immune Activating Cytokines With Genentech, Will Receive \$120M Upfront Payment, Up To \$180M In Development Milestones

Financial news for XNCR dated on 2019-01-07: Xencor Regains ex-U.S. Commercial Rights To XmAb13676, CD20 x CD3 Bispecific Antibody

Financial news for XNCR dated on 2018-11-05: Xencor Had \$525M In Cash, Cash Equivalents, Marketable Securities At End Of 2018, Says Has Sufficient Cash To Fund R&D Programs, Operations Into 2023

Financial news for XNCR dated on 2018-11-05: Xencor Q3 EPS \$0.05 Beats \$(0.52) Estimate, Sales \$29.039M Up From \$7.09M YoY

Financial news for XNCR dated on 2018-11-01: Xencor to Present Initial Data From Phase 1 Study Of XmAb14045 Bispecific Antibody In Acute Myeloid Leukemia At The 2018 ASH Annual Meeting Dec 1-4

Financial news for XNCR dated on 2018-10-05: UPDATE: Xencor Highlights 'Positive Trend' In XmAb5871 Primary Endpoint, Secondary Endpoint Met, Well Tolerated

Financial news for XNCR dated on 2018-10-05: Xencor Reports Topline Results From Phase 2 Study Of XmAb5871 In Systemic Lupus Erythematosus, Selection Of Late-Breaking Abstract For ACR

Financial news for XNCR dated on 2018-10-05: Xencor Announces Topline Results From Phase 2 Study Of XmAb5871 In Systemic Lupus Erythematosus; Met Secondary Endpoint, Reported 'Positive Trend' In Primary Endpoint

Financial news for XNCR dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for XNCR dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for XNCR dated on 2018-09-13: Stocks Which Set New 52-Week High Yesterday, September 12

Financial news for XNCR dated on 2018-09-10: BTIG Research Assumes Xencor at Buy, Announces Price Target \$56

Financial news for XNCR dated on 2018-08-14: 13F From Omega Shows Exited Stake In Acceleron Pharma, Xencor and Shell Midstream Partners

Financial news for XNCR dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for XNCR dated on 2018-08-06: Xencor Expects To Have Cash To Fund Research And Development Programs And Operations Into 2023

Financial news for XNCR dated on 2018-08-06: Xencor Q2 EPS \$(0.46) Beats \$(0.48) Estimate

Financial news for XNCR dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for XNCR dated on 2018-07-12: Xencor Doses First Patient In Phase 1

Study Of XmAb20717 Dual Checkpoint Inhibitor For The Treatment Of Advanced Solid Tumors

Financial news for XNCR dated on 2018-06-07: BTIG Research Initiates Coverage On Xencor with Buy Rating, Announces \$56 Price Target

Financial news for XNCR dated on 2018-05-07: Xencor Q1 EPS \$(0.62) Misses \$(0.46) Estimate

Financial news for XNCR dated on 2018-04-18: Xencor Presents Preclinical Data On XmAb 24306 At AACR: Showed 'engineered complex enhanced the duration and magnitude of T and NK cell proliferation in vitro and in vivo'

Financial news for XNCR dated on 2018-03-28: Leerink Swann Assumes Xencor at Outperform, Announces Price Target \$36.00

Financial news for XNCR dated on 2018-03-27: Xencor Shares Move Lower Over Last Few Mins. Despite Circulating Of Positive Recommendation From Agora Financial Newsletter

Financial news for XNCR dated on 2018-03-21: Xencor Shares Down 5.2% After Co. Earlier Priced 7.3M Share Public Offering At \$31/Share

Financial news for XNCR dated on 2018-03-19: Xencor Announces Offering Of 5M Shares

Financial news for XNCR dated on 2018-02-27: Xencor Reports Q4 GAAP EPS \$(0.25) May Not Compare To \$(0.35) Est., Sales \$10.9M vs \$6.8M Est.; Says Expects To Have Cash On Hand To Fund R&D Programs, Operations Beyond '20

Financial news for XNCR dated on 2018-02-26: Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Financial news for XNCR dated on 2018-02-22: Xencor Reports Dosing Of First Patient In Phase 1 Study Of XmAb 18087 Bispecific Tumor Targeting Antibody For Treatment Of Neuroendocrine Tumor, Gastrointestinal Stromal Tumors

Financial news for XNCR dated on 2018-02-22: Xencor Doses First Patient in Phase 1 Study of XmAb(r)18087

Financial news for XNCR dated on 2018-01-05: Xencor Highlights '18 Priorities, Expected Milestones

Financial news for XNCR dated on 2017-12-05: Xencor Receives a \$10M Milestone Payment from Amgen

Financial news for XNCR dated on 2017-11-29: Cantor Fitzgerald Initiates Coverage On Xencor with Overweight Rating, Announces \$33.00 Price Target

Financial news for XNCR dated on 2017-11-07: Xencor Reports Q3 EPS \$(0.33) In-line With Est., Sales \$7.1M vs \$6.32M Est.

Financial news for XNCR dated on 2017-10-20: Xencor Will Present Final Results From Phase 2 Study Of XmAb 5871 In IgG4-Related Disease At ACR Meeting; Says Has Been Accepted For Late-Breaking Abstract Session

Financial news for XNCR dated on 2017-08-07: Xencor Reports Q2 Loss/Share \$(0.15) vs. \$(0.25) Est., Sales \$13.3M vs. \$8.18M Est.

Financial news for XNCR dated on 2017-06-16: Xencor Reports Interim Data From Ongoing, Open-Labeled, Phase 2 Study Of XmAb 5871 In IgG4-Related Disease: 14 of 15 patients (93%) achieved a response to therapy, 12 of them within 2 weeks of first dose

Financial news for XNCR dated on 2017-05-11: Xencor's XmAb5871 Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease

Financial news for XNCR dated on 2017-05-09: Xencor Reports Q1 EPS \$(0.31) vs \$(0.24) Est., Sales \$4.3M vs \$5.73M Est.

Financial news for XNCR dated on 2017-03-02: Nomura Initiates Coverage On Xencor at Neutral

Financial news for XNCR dated on 2017-02-28: Xencor Sees Ending 2017 with ~\$340M in Cash, Cash Equivalents

Financial news for XNCR dated on 2017-02-28: Xencor Reports Q4 EPS \$(0.21) vs \$(0.32) Est., Sales \$6.44M vs \$5.61M Est.

Financial news for XNCR dated on 2016-10-04: PiperJaffray Initiates Coverage on

Xencor at Overweight

Financial news for XNCR dated on 2014-12-07: MorphoSys, Xencor Publish Final Results from Phase 1/2a Trial of MOR208 in CLL/SLL at ASH Annual Meeting

Financial news for XNCR dated on 2014-07-31: Xencor Announces Q2 Revenue \$0.8M, EPS -\$0.16 - May Not Compare

Financial news for XNCR dated on 2014-07-16: Morning Market Losers

Financial news for XNCR dated on 2014-05-28: Xencor Initiates Phase 1 Study of XmAb7195

Financial news for XNCR dated on 2014-04-17: Adam Feuerstein Tweet:. @CramersShirt Still early but I really like \$XNCR

Financial news for XNCR dated on 2013-12-30: Benzinga's Top Initiations

Financial news for XNCR dated on 2013-12-03: Xencor Opens for Trade at \$5.95, Priced at \$5.50/Share